Department of Biotechnology, Faculty of Natural Sciences, Jamia Millia Islamia, New Delhi, India.
Adv Exp Med Biol. 2020;1229:121-132. doi: 10.1007/978-981-15-1671-9_6.
Cardiovascular Diseases (CVDs) as a leading cause of death worldwide inflict major stress on morbidity and societal costs. Though the studies pertaining to pathophysiology and genetics of CVDs have helped in prevention, diagnosis and treatment of diseases, there are still lacunas in our knowledge. So, novel tools that can define genomic regulation under different conditions are needed to bridge this gap. 'Epigenetic' mechanism helps the cells to quickly respond to ever changing environment by molecular mechanisms like methylation, histone modifications, nc-RNAs. These mechanisms act as a new layer of regulation in CVDs. The role of epigenetics as a key regulatory player in prevention, diagnosis and treatment of CVDs is emerging. Thus, the focus of present chapter is to decipher the role of epigenetics in CVDs and its potential to be used in risk assessment or as biomarkers in devising and deploying better diagnosis and treatment for different CVDs.
心血管疾病 (CVDs) 作为全球主要的死亡原因，给发病率和社会成本带来了重大压力。尽管与 CVDs 的病理生理学和遗传学相关的研究有助于预防、诊断和治疗疾病，但我们的知识仍存在空白。因此，需要新的工具来定义不同条件下的基因组调控，以弥补这一差距。“表观遗传”机制通过甲基化、组蛋白修饰、nc-RNAs 等分子机制帮助细胞快速应对不断变化的环境。这些机制在 CVDs 中充当了新的调控层。表观遗传作为 CVDs 预防、诊断和治疗的关键调控因子的作用正在显现。因此，本章的重点是阐明表观遗传在 CVDs 中的作用及其在风险评估或作为生物标志物中的潜在应用，以设计和部署针对不同 CVDs 的更好的诊断和治疗方法。
